SAB Biotherapeutics's total assets for Q3 2023 were $28.34M, a decrease of -20.05% from the previous quarter. SABS total liabilities were $13.08M for the fiscal quarter, a -16.82% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.